CrownBio Reveals Plans for Louisiana Research Facility

By Evelina Croitoru

401 W. Admiral Doyle Drive, New Iberia, La.

New Iberia, La.—Crown Bioscience Inc. announced that the company will develop a pharmaceutical research and development facility at the New Iberia Research Center, located at 401 W. Admiral Doyle Drive, in New Iberia, La. The company will invest $1 million in the facility that will enable CrownBio to advance treatments for cardiovascular and metabolic disease research.

“We chose to expand in Louisiana, and specifically the NIRC, because of the growing biomedical science community there and the operational excellence that exists at NIRC. It was important for us to be located at a facility with multiple research capabilities that could harmonize well with the various efficacy and model development studies conducted by CrownBio,” said Jean-Pierre Wery, CEO of CrownBio, in prepared remarks. “We are confident Louisiana and NIRC, is the place for CrownBio to grow as we engage in the next leading phase of CVMD research that brings drugs to the clinical phase. We are very excited to contribute positively to the economic growth of the New Iberia region.”

In its research efforts, the company will join forces with the NIRC, which is an affiliate of the University of Louisiana that specializes in the management of nonhuman primates for applied and basic research. The new center will enable CrownBio to enhance its research and surpass the capacity it has in North Carolina, in addition to expanding its research services in Louisiana.

“Our center in New Iberia has the research and analytical expertise and infrastructure in place to assist CrownBio to respond to the needs of its global clientele very quickly. We are committed to incubating and growing businesses in the biomedical arena, supported by the strength of UL Lafayette’s research in life sciences,” François Villinger, director of NIRC, said in prepared remarks.

Image via Google Maps